During the corresponding time, Paragon 28 Inc recorded a revenue increase by 20.53 % year on year, sequentially revenue grew by 16.31 %. While revenue at the Paragon 28 Inc 's corporate clients
Paragon 28 Inc's Comment on Sales, Marketing and Customers
The company operates in the foot and ankle medical device market, addressing multiple sub-categories including fracture fixation, forefoot, ankle, PCFD (flatfoot), Charcot foot, and orthobiologics. Its product portfolio also encompasses soft tissue, sports medicine, orthobiologics, and analytical solutions within these areas. The United States represents the largest market for foot and ankle procedures and product sales, with international sales in 23 countries accounting for approximately 17% of revenue in 2024. The company maintains a U.S. sales force of 249 producing representatives and initiated international sales in late 2016. Since 2011, it has launched over 80 product lines and currently has more than 30 product and system offerings in development. Its customer base includes medical providers across various segments of the foot and ankle market. Market growth is influenced by demographic trends such as an aging population, rising rates of obesity and diabetes, and increased patient demand for active lifestyles. Customers and markets referenced in company filings include Additive Orthopaedics and Disior Oy.
Stepping Into the Spotlight: Paragon 28 Debuts on the J.P. Morgan Stage In the ever-evolving landscape of medical technology, Paragon 28, Inc. has carved a niche as a front-runner in the foot and ankle orthopaedic market. The Colorado-based company, listed on the New York Stock Exchange under the ticker FNA, is poised to present at the prestigious 43rd Annual J.P. Morgan Healthcare Conference. On Monday, January 13, 2025, at precisely 7:30 a.m. Pacific Time, Albert DaCosta, the Chairman and CEO, alongside Chadi Chahine, CFO and Executive Vice President of Supply Chain Operations, will illuminate the conference with insights into their innovative roadmap.In a market saturated with giants, Paragon 28’s parti...
Paragon 28 to Showcase Innovations and Leadership at the 43rd Annual J.P. Morgan Healthcare Conference ENGLEWOOD, Colo. Paragon 28, Inc. (NYSE: FNA), a prominent figure in the medical device sector focusing solely on foot and ankle orthopedic solutions, is set to present at the illustrious 43rd Annual J.P. Morgan Healthcare Conference. The event will take place on Monday, January 13, 2025, at 7:30 a.m. Pacific Time / 8:30 a.m. Mountain Time. Spearheading the presentation at the conference will be Albert DaCosta, Chairman and CEO, alongside Chadi Chahine, CFO and EVP of Supply Chain Operations. This opportunity reflects the company s commitment to innovation and leadership in the niche field of orthopedic d...
Paragon 28, Inc. (NYSE: FNA) has announced the launch of its latest product, the Phantom Fibula Nail System, a less invasive surgical solution for treating ankle fractures. This cutting-edge system is designed to provide orthopedic surgeons with an alternative to traditional plate and screw fixation, now recognized as a common technique for repairing fibular injuries.The Phantom Fibula Nail System presents a significant advancement in surgical technology, particularly in its effectiveness in reducing soft tissue complications, the frequency of implant removals, and the risk of fracture nonunion. Traditionally, the treatment of ankle fractures has been associated with higher rates of postoperative complicatio...
By August 7, 2024, SAN DIEGO The Denver, Colorado office of Johnson Fistel, LLP, a well-respected shareholder rights law firm, has recently announced an investigation into Paragon 28, Inc. (NYSE: FNA), a medical devices company headquartered in Englewood, Colorado. This probe seeks to determine whether Paragon 28 or its executive officers have violated securities laws through misrepresentation or a failure to disclose material, adverse information to its investors promptly.The announcement comes amid growing concerns among shareholders about the integrity of the company s financial disclosures. Johnson Fistel s investigation focuses on the possibility that Paragon 28 may have engaged in practices that m...
Paragon 28: Revolutionizing Ankle Injury Treatments with the Launch of Grappler R3INFORCE Extraosseous Repair SystemENGLEWOOD, Colo. - Paragon 28, a renowned medical device company, has announced the exciting launch of their latest product, the Grappler R3INFORCE Extraosseous Repair System. This innovative solution is specifically designed to restore stability to the anterior and posterior ligaments surrounding the ankle during fibula fracture repairs and high ankle sprains. The introduction of this advanced system marks another significant addition to Paragon 28 s suite of novel syndesmosis repair solutions.Ankle injuries, such as fibula fractures and high ankle sprains, are common among athletes and indivi...
Paragon 28 Inc’s Comment on Sales, Marketing and Customers
The company operates in the foot and ankle medical device market, addressing multiple sub-categories including fracture fixation, forefoot, ankle, PCFD (flatfoot), Charcot foot, and orthobiologics. Its product portfolio also encompasses soft tissue, sports medicine, orthobiologics, and analytical solutions within these areas. The United States represents the largest market for foot and ankle procedures and product sales, with international sales in 23 countries accounting for approximately 17% of revenue in 2024. The company maintains a U.S. sales force of 249 producing representatives and initiated international sales in late 2016. Since 2011, it has launched over 80 product lines and currently has more than 30 product and system offerings in development. Its customer base includes medical providers across various segments of the foot and ankle market. Market growth is influenced by demographic trends such as an aging population, rising rates of obesity and diabetes, and increased patient demand for active lifestyles. Customers and markets referenced in company filings include Additive Orthopaedics and Disior Oy.
Sources:
Paragon 28 inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Paragon 28 inc’s corporate clients.
For your research, we’ve provided 9 tables on Paragon 28 inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
82.28 %